News
Talecris offers stock in initial public offering
bizjournals.com
Talecris Biotherapeutics Friday filed an initial public offering of stock projected to raise more than $800 million.
The company makes protein therapies derived from blood plasma, including Prolastin for Alpha-1 Antitrypsin Deficiency.
The Research Triangle Park-based company, in a filing with the U.S. Securities and Exchange Commission, unveiled plans Friday to offer almost 29 million shares of its common stock in an IPO priced between $18 and $20. Based on an IPO price of $19, Talecris expects to pocket $514.8 million, which the company says it will use to pay off debt.
In addition, the two private equity firms that own 97 percent of Talecris – Cerberus Capital Management and Ampersand Ventures – will sell almost 16 million shares of the company’s stock. Based on an IPO price of $19, the two firms will pocket about $300 million – which is the amount they paid Bayer AG in 2005 to buy the company’s plasma division.
